Search

Your search keyword '"treprostinil"' showing total 960 results
Start Over Descriptor "treprostinil" Topic business
960 results on '"treprostinil"'

1. United Therapeutics price target raised by $25 at Oppenheimer, here's why

Subjects
Treprostinil, Business, News, opinion and commentary
Abstract

Oppenheimer raised the firm's price target on United Therapeutics to $600 from $575 and keeps an Outperform rating on the shares following quarterly results. The firm says 'robust' Q3 financials [...]

Published
2024

2. United Therapeutics price target raised by $25 at Ladenburg, here's why

Subjects
Treprostinil, Business, News, opinion and commentary, Tyvaso (Medication)
Abstract

Ladenburg raised the firm's price target on United Therapeutics to $344 from $319 and keeps a Buy rating on the shares following the Q3 report. The firm expects the growth [...]

Published
2024

3. Liquidia initiated with bullish view at Scotiabank, here's why

Subjects
Treprostinil, Pulmonary hypertension, Business, News, opinion and commentary
Abstract

Scotiabank initiated coverage of Liquidia (LQDA) with an Outperform rating and $30 price target. As Liquidia's legal battle with competitor United Therapeutics (UTHR) over Tyvaso comes to a close, the [...]

Published
2024

4. Liquidia price target lowered by $3 at H.C. Wainwright, here's why

Subjects
Treprostinil, Business, News, opinion and commentary
Abstract

H.C. Wainwright lowered the firm's price target on Liquidia (LQDA) to $29 from $32 and keeps a Buy rating on the shares. The analyst believes United Therapeutics (UTHR) effectively delayed [...]

Published
2024

5. Insmed price target raised by $8 at Wells Fargo, here's why

Subjects
Wells Fargo & Co., Banking industry, Treprostinil, Banking industry, Business, News, opinion and commentary
Abstract

Wells Fargo analyst Tiago Fauth raised the firm's price target on Insmed to $85 from $77 and keeps an Overweight rating on the shares. The firm thinks Treprostinil Palmitil Inhalation [...]

Published
2024

6. Liquidia reports Q2 EPS (37c), consensus (34c)

Subjects
Treprostinil, Company earnings/profit, Business, News, opinion and commentary
Abstract

Reports Q2 revenue $3.66M, consensus $9.45M. Cash and cash equivalents totaled $133.1M as of June 30 compared to $83.7M as of December 31, 2023. The company said, 'Revenue related primarily [...]

Published
2024

7. Roivant Sciences Ltd Unveiling New Pipeline Program: Mosliciguat - Final

Subjects
Merck & Company Inc., Bayer AG, Pipe lines, Treprostinil, Pharmaceutical industry, Business, Tyvaso (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Welcome to Roivant investor call this morning. (Operator Instructions) Please be advised that today's conference is being recorded. I would [...]

Published
2024

8. MannKind Corp at Morgan Stanley Global Healthcare Conference - Final

Subjects
Morgan Stanley, Mannkind Corp., Treprostinil, Securities industry, Pharmaceutical industry, Securities industry, Business, Tyvaso (Medication)
Abstract

Presentation SAM JONES, ANALYST, MORGAN STANLEY: Great. Well, good morning, everybody. Thanks for joining us today. I'm [Sam Jones from the Morgan Stanley] team, and I'm excited to have joining [...]

Published
2024

9. Liquidia reports Q1 EPS (54c), consensus (32c)

Subjects
Treprostinil, Pulmonary hypertension, Company earnings/profit, Business, News, opinion and commentary
Abstract

Reports Q1 revenue $2.97M, consensus $4.39M. Cash and cash equivalents totaled $157.9M as of March 31, compared to $83.7M as of December 31, 2023. Roger Jeffs, Liquidia's CEO, said: 'We [...]

Published
2024

10. Gossamer Bio Inc To Host Update Call - Final

Subjects
Cardiovascular agents, Respiratory agents, Chief operating officers, Treprostinil, Chief financial officers, Pulmonary hypertension, Business
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen, and welcome to the Gossamer Bio announcement presentation. I will now turn the presentation over to Bryan Giraudo. BRYAN GIRAUDO, CHIEF FINANCIAL OFFICER, [...]

Published
2024

11. Insmed price target raised by $3 at Barclays, here's why

Subjects
Treprostinil, Business, News, opinion and commentary
Abstract

Barclays raised the firm's price target on Insmed to $40 from $37 and keeps an Overweight rating on the shares. The analyst sees 'compelling reasons to be optimistic' on treprostinil [...]

Published
2024

12. Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA(TM) (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD

Subjects
United States. Food and Drug Administration, United Therapeutics Corp., Actions and defenses, Biotechnology industry, Treprostinil, Drug approval, Pulmonary hypertension -- Care and treatment, Lawsuit/litigation, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

MORRISVILLE, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it has filed [...]

Published
2024

13. U.S. FDA Grants Tentative Approval of YUTREPIA(TM) (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Subjects
United States. Food and Drug Administration, Lung diseases -- Care and treatment, Treprostinil, Drug approval, Pulmonary hypertension -- Care and treatment, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic [...]

Published
2024

14. United Therapeutics Corp at Leerink Partners Global Biopharma Conference - Final

Subjects
United Therapeutics Corp., Biological products industry, Medical research, Medicine, Experimental, Treprostinil, Business, Tyvaso (Medication)
Abstract

Presentation ROANNA CLARISSA H. RUIZ, SENIOR MD OF INFECTIOUS DISEASE, ENDOCRINE & CARDIOVASCULAR DISORDERS & SENIOR RESEARCH ANALYST, LEERINK PARTNERS LLC, RESEARCH DIVISION: Well, welcome, everyone. Thanks to come back [...]

Published
2024

15. LIFE SCIENCES

Subjects
Pfizer Inc., Treprostinil, Pharmaceutical industry, Business, Business, regional
Abstract

North Carolina continues to gain prominence as a major life sciences state with investments from both large pharmaceutical companies and innovative new businesses and startups. Clusters of manufacturers have developed [...]

Published
2022

16. Liquidia and Pharmosa expand collaboration for inhaled treprostinil

Subjects
Treprostinil, Business
Abstract

M2 EQUITYBITES-October 2, 2024-Liquidia and Pharmosa expand collaboration for inhaled treprostinil (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, [...]

Published
2024

17. United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Subjects
United Therapeutics Corp., Medical research, Medicine, Experimental, Pulmonary fibrosis -- Care and treatment -- Development and progression, Biotechnology industry, Treprostinil, Business, Business, international, Tyvaso (Medication)
Abstract

Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half [...]

Published
2024

19. Insmed to Host Commercial Webinar on June 4, 2024

Subjects
Insmed Inc., Antibacterial agents, Treprostinil, Aminoglycosides, Pharmaceutical industry, Business, News, opinion and commentary, Arikayce (Medication)
Abstract

BRIDGEWATER, N.J., May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host [...]

Published
2024

20. Insmed Announces Pricing of $650 Million Public Offering of Common Stock

Subjects
Insmed Inc., Patient compliance, Stocks, Treprostinil, Pharmaceutical industry, Business, News, opinion and commentary, Arikayce (Medication)
Abstract

BRIDGEWATER, N.J., May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today [...]

Published
2024

21. Liquidia Corp at JPMorgan Healthcare Conference - Final

Subjects
Treprostinil, Business
Abstract

Presentation HARRY PEARSON JPMORGAN, MODERATOR: Thank you for joining us this morning. My name is Harry Pearson and a member of JPMorgan's Investment Banking team. I'm pleased to welcome you [...]

Published
2024

22. BioXcel Therapeutics Inc To Host Neuroscience R&D Day - Final

Subjects
Pfizer Inc. -- Officials and employees, Dexmedetomidine, Treprostinil, Pharmaceutical industry -- Officials and employees, Neurophysiology, Business
Abstract

Presentation OPERATOR: Greetings, and welcome to the BioXcel Therapeutics Neuroscience R&D Day. At this time, I'd like to turn the call over to Dr. Frank Yocca of BioXcel. Thank you, [...]

Published
2023

23. Liquidia reports Q1 EPS (18c), consensus (16c)

Subjects
Treprostinil, Pulmonary hypertension, Company earnings/profit, Business, News, opinion and commentary
Abstract

Reports Q1 revenue $4.5M, consensus $3.95M. Roger Jeffs, CEO, said: 'We have heard from the physician community about the increasing demand for inhaled treprostinil to treat both pulmonary arterial hypertension [...]

Published
2023

25. United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference

Subjects
United Therapeutics Corp., Societies, Biotechnology industry, Conferences and conventions, Treprostinil, Associations, institutions, etc., Business, Business, international
Abstract

Initial, interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open label study to be presented at a poster discussion session An annual update of the preliminary baseline [...]

Published
2024

26. Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA(TM) (treprostinil) inhalation powder

Subjects
United States. Food and Drug Administration, Treprostinil, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman Litigation On March 29, Judge Bates denied United Therapeutics' motion for temporary restraining order and preliminary [...]

Published
2024

27. Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Subjects
Insmed Inc., Societies, Lung diseases, Patient compliance, Treprostinil, Mediation, Associations, institutions, etc., Pharmaceutical industry, Business, News, opinion and commentary, Arikayce (Medication)
Abstract

-Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker- -Data to [...]

Published
2024

28. Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

Subjects
United States. Food and Drug Administration, United States. Court of Appeals for the Federal Circuit, Silicon Valley Bank -- Company sales and earnings, United Therapeutics Corp. -- Company sales and earnings, Biotechnology industry -- Company sales and earnings, Banking industry -- Company sales and earnings, Treprostinil, Company earnings/profit, Banking industry, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

Preparing to launch YUTREPIA(TM) (treprostinil) inhalation powder upon final FDA approval Federal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding '793 Patent invalid Advancing industry leading [...]

Published
2024

29. United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process

Subjects
United States. Food and Drug Administration, United Therapeutics Corp., Independent regulatory commissions, Actions and defenses, Treprostinil, Drug approval, Patent infringement, Lawsuit/litigation, Business, Business, international, Tyvaso (Medication)
Abstract

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the commencement of litigation with the United States Food and Drug Administration (FDA). In [...]

Published
2024

30. Insmed prices of USD650 million public offering of common stock

Subjects
Insmed Inc., Stocks, Treprostinil, Pharmaceutical industry, Business
Abstract

M2 EQUITYBITES-May 31, 2024-Insmed prices of USD650 million public offering of common stock (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Insmed Incorporated (Nasdaq: INSM), a US-based global biopharmaceutical, announced on Thursday that it [...]

Published
2024

31. Dr. Reddy's launches Treprostinil Injection in the U.S

Subjects
Generic drugs, Treprostinil, Drug approval, Business, News, opinion and commentary, Remodulin (Medication)
Abstract

Dr. Reddy's announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin Injection, approved by the [...]

Published
2023

32. Liquidia Corp Corporate Call - Final

Subjects
Treprostinil, Chief financial officers, Business, Tyvaso (Medication)
Abstract

Presentation OPERATOR: Good morning, and welcome, everyone to the Liquidia Corporation Corporate Update Call. My name is Liz, and I will be your conference operator today. (Operator Instructions) I would [...]

Published
2023

34. Liquidia Corporation Provides Update on New Drug Application for YUTREPIA(TM) (treprostinil) inhalation powder

Subjects
United States. Food and Drug Administration, United Therapeutics Corp., Drugs -- Prescribing, Biotechnology industry, Treprostinil, Pulmonary hypertension, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review [...]

Published
2024

35. Liquidia Corporation Announces Updates to Operations Leadership

Subjects
Business plans, Chief operating officers, Treprostinil, Business planning, Chief financial officers, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the potential [...]

Published
2024

36. Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Subjects
United States. Food and Drug Administration, Pipe lines, Lung diseases, Treprostinil, Pulmonary hypertension, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C., [...]

Published
2024

37. Liquidia Corporation Announces $100 Million in New Financings

Subjects
Private placements (Securities), Treprostinil, Banking, finance and accounting industries, Business
Abstract

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement Additional advance of $25.0 million from HealthCare Royalty under current financing [...]

Published
2024

38. MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million

Subjects
Mannkind Corp., United Therapeutics Corp., Biotechnology industry, Treprostinil, Pharmaceutical industry, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

Sagard Healthcare purchased a 1% royalty in Tyvaso DPI [sup. (R) ] net sales Purchase price of $150 million; additional potential milestone payment of up to $50 million WESTLAKE VILLAGE, [...]

Published
2024

39. Liquidia Announces Pricing of Public Offering of Common Stock

Subjects
Stocks, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a [...]

Published
2023

40. United Therapeutics assumed with an Outperform at Wedbush

Subjects
Treprostinil, Business, News, opinion and commentary, Tyvaso (Medication)
Abstract

Wedbush analyst Andreas Argyrides assumed coverage of United Therapeutics with an Outperform rating and $263 price target. The analyst considers United Therapeutics an opportunity to invest in proven growth through [...]

Published
2022

41. United Therapeutics 'pleased' with court decision in patent litigation

Subjects
United Therapeutics Corp., Actions and defenses, Treprostinil, Patent infringement, Lawsuit/litigation, Business, News, opinion and commentary
Abstract

United Therapeutics Corporation (UTHR) announced that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics' U.S. patents 9,593,066 and [...]

Published
2022

42. Liquidia stay denial not 'a material setback,' says BofA

Subjects
Treprostinil, Business, News, opinion and commentary
Abstract

BofA analyst Greg Harrison notes that Liquidia (LQDA) shares are under significant pressure after a decision from the U.S. District Court denying Liquidia's request to stay a decision on the [...]

Published
2022

43. United Therapeutics reports Q2 EPS $2.41, consensus $4.12

Subjects
Treprostinil, Drug approval, Pulmonary hypertension, Company earnings/profit, Business, News, opinion and commentary, Tyvaso (Medication)
Abstract

Reports Q2 revenue $466.9M, consensus $461.06M. 'I'm extraordinarily pleased with our business performance this past quarter,' said CEO Martine Rothblatt. 'The FDA's approval of our Tyvaso DPI medicine and recent [...]

Published
2022

44. Liquidia announces publication of long-term clinical data from INSPIRE study

Subjects
Treprostinil, Pulmonary hypertension -- Care and treatment, Business, News, opinion and commentary, Tyvaso (Medication)
Abstract

Liquidia announced the publication of clinical data from the completed INSPIRE study evaluating YUTREPIA inhalation powder, formerly known as LIQ861, in patients with pulmonary arterial hypertension in the journal Pulmonary [...]

Published
2022

45. Ladenburg starts Liquidia Technologies at Buy with $15 price target

Subjects
Treprostinil, Business, News, opinion and commentary
Abstract

Ladenburg analyst Matt Kaplan initiated coverage of Liquidia Technologies (LQDA) with a Buy rating and $15 price target. Lead asset Yutrepia is a dry powder inhaler of treprostinil being developed [...]

Published
2022

46. Liquidia Technologies price target raised to $17 from $14 at BTIG

Subjects
Treprostinil, Appellate procedure, Business, News, opinion and commentary
Abstract

BTIG analyst Julian Harrison raised the firm's price target on Liquidia Technologies to $17 from $14 and keeps a Buy rating on the shares. The analyst cites the ruling by [...]

Published
2022

47. United Therapeutics price target raised to $263 from $236 at Wedbush

Subjects
Treprostinil, Drug approval, Business, News, opinion and commentary, Tyvaso (Medication)
Abstract

Wedbush analyst Liana Moussatos raised the firm's price target on United Therapeutics to $263 from $236 and keeps an Outperform rating on the shares after the FDA approved Tyvaso DPI [...]

Published
2022

48. MannKind's Technosphere inhalation platform utilized in FDA-approved Tyvaso DPI

Subjects
United States. Food and Drug Administration, Treprostinil, Pulmonary hypertension -- Drug therapy, Business, News, opinion and commentary, Tyvaso (Medication)
Abstract

MannKind (MNKD) celebrated that the U.S. FDA has approved United Therapeutics' (UTHR) Tyvaso DPI inhalation powder for the treatment of patients with pulmonary arterial hypertension and pulmonary hypertension associated with [...]

Published
2022

49. United Therapeutics announces FDA approval of Tyvaso DPI

Subjects
United States. Food and Drug Administration, Treprostinil, Pulmonary hypertension -- Drug therapy, Business, News, opinion and commentary, Tyvaso (Medication)
Abstract

United Therapeutics announced that the U.S. FDA has approved Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve [...]

Published
2022

50. United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis

Subjects
United Therapeutics Corp., Medical research, Medicine, Experimental, Pulmonary fibrosis -- Care and treatment, Biotechnology industry, Treprostinil, Business, Business, international, Tyvaso (Medication)
Abstract

Up to 60,000 patients in the United States may have PPF, with only one approved therapy available SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. -- United Therapeutics Corporation (Nasdaq: [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results